At a time when restrictions on the prescribing of buprenorphine have been relaxed nationally in order to expand access to evidence‐based treatment, a group of physicians in Kentucky has expressed concern that state regulators are dangerously moving in the opposite direction.
No takes yet. Share an insight, caveat, or question.
Gary Enos (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: